Graves’ Disease
-
Roivant: Novel Data on Graves’ Disease Treatment Suggests Paradigm Shift
Immunovant announced positive six-month remission data for batoclimab in uncontrolled Graves’ disease. ~80% of patients (17/21) maintained normal thyroid function after stopping treatment, with ~50% (8/17) achieving complete remission without anti-thyroid drugs. Another 30% needed only minimal doses. IMVT-1402, is being evaluated in two trials with results expected in 2027. This therapy targets the autoimmune root of Graves’ disease by blocking FcRn. If successful, this could significantly improve treatment for Graves’ disease patients.
